Form 4 for CRSP CRISPR Therapeutics AG
Accepted 2024-01-31 00:00:00 ET · period of report 2024-01-29 · accession 0000950170-24-009505 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2024-01-31 | 2024-01-29 | CRSP | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $60.51 | -50.0K | 188.1K | -21% | -$3.03M |
| DT | 2024-01-31 | 2024-01-29 | CRSP | Kulkarni Samarth | CEO, Dir | M - OptEx | $19.12 | +50.0K | 237.4K | +27% | +$956.0K |
| DT | 2024-01-31 | 2024-01-29 | CRSP | Kulkarni Samarth | CEO, Dir | M - OptEx | — | -50.0K | 100.0K | -33% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2024-01-29 | S | D | 700 | $61.10 | 187,377 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.04 to $61.155, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 2 | Common | Common Shares | 2024-01-29 | S | D | 49,300 | $60.50 | 188,077 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.04 to $61.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 3 | Common | Common Shares | 2024-01-29 | M | A | 50,000 | $19.12 | 237,377 | D | — | — | |
| 4 | Derivative | Stock Option (Right to Buy) | 2024-01-29 | M | D | 50,000 | — | 100,000 | D | $19.12 · — to 2027-12-01 | 50,000 Common Shares | (F5) Not applicable. (F4) This performance-based stock option was granted on December 1, 2017 with respect to 150,000 Common Shares and was subject to both time- and performance-based vesting. Performance-based stock options vested as to 112,500 options on December 1, 2020 and 37,500 options on December 1, 2021, based on the Company's performance over the applicable performance period, and subject to the terms and conditions of the agreement evidencing the award and the Company's 2016 Stock Option and Incentive Plan. |